<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02166814</url>
  </required_header>
  <id_info>
    <org_study_id>BR-FRC-CT-301</org_study_id>
    <nct_id>NCT02166814</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of combination of
      Fimasartan/Rosuvastatin in comparison to each component administered alone in patients with
      essential hypertension and dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change rate of LDL-C at week 8 of Fimasartan/Rosuvastatin combination administration from the Baseline to compare the one of Fimasartan 120mg single administration</measure>
    <time_frame>8 weeks from Baseline Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of SiSBP at week 8 of Fimasartan/Rosuvastatin combination administration from the Baseline to compare the one of Rosuvastatin 20mg single administration</measure>
    <time_frame>8 weeks from Baseline Visit</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Essential Hypertension, Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Fimasartan and Rosuvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of Fimasartan and Rosuvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fimasartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fimasartan monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan and Rosuvastatin</intervention_name>
    <arm_group_label>Fimasartan and Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fimasartan</intervention_name>
    <arm_group_label>Fimasartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who voluntarily signed informed consent for participating in this clinical
             trial

          2. Male and female between 20 and 75 years old

          3. Patients must have been confirmed essential hypertension and dyslipidemia at Screening
             visit (Visit1)

          4. Patients who meet the following criteria of fasting LDL-C and blood pressure at
             Baseline visit (Visit3) assessment after undergoing the therapeutic lifestyle change.

               -  Low risk group: the case that does not have any other risk factor apart from
                  hypertension / LDL-C (mg/dL): ≥160, ≤250, Mean SiSBP(mmHg): ≥140, &lt;180

               -  Moderate risk group: the case that has more than or equal to one risk factor
                  apart from hypertension and has the 10-year risk of less than 10% / LDL-C
                  (mg/dL): ≥160, ≤250, Mean SiSBP(mmHg): ≥140, &lt;180

               -  Moderate high risk group: the case that has more than or equal to one risk factor
                  apart from hypertension and has the 10-year risk between 10% and 20% / LDL-C
                  (mg/dL): ≥130, ≤250, Mean SiSBP(mmHg): ≥140, &lt;180

               -  High risk group: the case of CHD (Coronary heart disease) or CHD risk equivalents

                    -  Risk factors include cigarette smoking, hypertension (BP≥140/90 mmHg or on
                       antihypertensive medication), low HDL cholesterol (&lt;40mg/dL), family history
                       of premature CHD(CHD in male first-degree relative &lt;55 years of age; CHD in
                       female first-degree relative &lt; 65 years of age), and age (men≥45 years;
                       women ≥55 years). in case of HDL-C ≥60mg/dL, reduce 1 from the total number
                       of risk factors.

                    -  Electronic 10 year risk calculators are available at
                       www.nhlbi.nih.gov/guidelines/cholesterol

                    -  CHD includes history of myocardial infarction, unstable angina, coronary
                       artery procedures (angioplasty or bypass surgery), or evidence of clinically
                       significant myocardial ischemia.

                    -  CHD risk equivalents include atherosclerotic disease (peripheral arterial
                       disease, abdominal aortic aneurysm and carotid artery disease [transient
                       ischemic attacks or stroke of carotid origin or &gt;50% obstruction of a
                       carotid artery]), diabetes and 2+ risk factors with 10 year risk of over 20%

          5. Subject must be able to understand the trial procedures and be willing to cooperate
             and complete the trial.

        Exclusion Criteria:

          1. Severe hypertension patients with mean siSBP ≥ 180mmHg and/or SiDBP ≥110mmHg at the
             assessment of Screening visit (Visit1) and/or Baseline visit (Visit3). Or patients
             with postural hypotension with manifestation.

          2. Patients with the mean SiSBP from 3 times of measurement of over 20mmHg.

          3. Secondary hypertension patients, but not limited to the following disease (example:
             renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of
             the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis,
             Cushing's syndrome, pheochromocytoma, polycystic kidney disease, etc)

          4. Secondary dyslipidemia: nephrotic syndrome, dysproteinemia, obstructive hepatopathy or
             Cushing's syndrome.

          5. Patients with fasting TG ≥ 400mg/dL at Pre-Baseline visit (Visit2) assessment

          6. History of myopathy, rhabdomyolysis or/and CK ≥ 2 times upper normal limit.

          7. Use of lipid modifying drug within 4 weeks prior to Pre-Baseline visit (Visit2) and/or
             antihypertensive drug within 2 weeks prior to Pre-Baseline visit(Visit2)

          8. Clinically significant renal function abnormality in the laboratory results at
             Pre-Baseline visit (i.e. serum creatinine ≥ 1.5 times upper normal limit), liver
             function abnormality (ALT, AST ≥ 2 times upper normal limit), severe fatty liver
             disease that requires medication.

          9. Clinically significant hypokalemia(less than 3.5 mmol/L) or hyperkalemia (exceeded 5.5
             mmol/L) measured at Pre-Baseline visit (Visit2)

         10. Subjects with following surgical and internal disease that may affect absorption,
             distribution, metabolism or excretion of drugs and have conditions which include the
             following (but are not limited to): history of major gastrointestinal surgeries
             including gastrectomy, gastro-enterostomy or bowel resection, gastrointestinal bypass
             graft and stabling; current active gastritis, ulcer, gastrointestinal and rectal
             bleeding, presence of active inflammatory bowel syndrome or biliary obstruction with
             the past 12 months.

         11. Subjects with depletion of body fluid or sodium ion not able to correct

         12. Subjects with sever insulin-dependent Diabetes Mellitus(DM) or Chronic DM (HbA1c &gt; 9%
             at Pre-Baseline visit, dosage of an oral hypoglycemic agent was modified within 12
             weeks prior to screening visit , or currently use of active insulin treatment) or with
             hypothyroidism not able to correct.( TSH ≥ 1.5 times upper normal limit)

         13. Subjects with severe heart disease (Heart failure New York Heart Association(NYHA)
             class 3 and 4), or history of any of the followings within the past 6 months; ischemic
             heart disease (e.g. angina pectoris, myocardial infarction), peripheral vascular
             disease, percutaneous transluminal coronary angioplasty, or coronary artery bypass
             graft.

         14. Subjects with clinically significant ventricular tachycardia, atrial fibrillation,
             atrial flutter or any other clinical significant arrhythmia conditions at discretion
             of investigator

         15. Subjects with hypertrophic obstructive cardiomyopathy, severe obstructive coronary
             artery disease, aortic stenosis, hemodynamically significant aortic valve stenosis, or
             mitral valve stenosis.

         16. Subjects with severe cerebrovascular disorder (e.g. stroke, cerebral infarction or
             cerebral hemorrhage within the past 6 months)

         17. Subjects with chronic inflammatory disease requiring an chronic anti-inflammatory
             therapy, past or current medical history with wasting disease, autoimmune diseases
             (e.g. rheumatoid arthritis, systemic lupus erythematosus) or connective tissue
             disease.

         18. Subjects with known moderate or malignant retinosis (e.g. retinal hemorrhage, visual
             disturbance or retinal microaneurysm in the past 6 months)

         19. Subjects with hepatitis B (including positive test for HBsAg), hepatitis C-positive

         20. Subjects with history or evidence of abusing drugs or alcohol within the past 2 years.

         21. Medical history with hypersensitivity to angiotensin II antagonist based drugs or
             HMG-CoA reductase inhibitor based drugs or any ingredient contained in these 2 drugs.

         22. Medical history with clinically significant hypersensitivity to any components or
             other drugs on the investigational product or additives (yellow 5)

         23. Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency
             or glucose-galactose malabsorption.

         24. Pregnant women and lactating female.

         25. Subjects planning pregnancy or childbearing potential who are not using effective
             contraceptive methods (surgical sterilized, intrauterine (contraceptive) device/condom
             or the combination of diaphragm and spermicidal agents)

         26. Subjects who are participating in another trial or took other investigational product
             within 12 weeks prior to Screening visit

         27. Medical history of all kinds of malignant tumor including leukemia and lymphoma in the
             past 5 years

         28. A subject with other reasons not specified above that, ineligible to participate in
             this clinical trial at discretion of study investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongjoo Oh</last_name>
    <role>Study Chair</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul university Bundang hospital</name>
      <address>
        <city>Bundang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dong-A university hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje Heaundai Paik hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje university Busan Paik hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ChungNam university hospital</name>
      <address>
        <city>ChungNam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DanGuk university hospital</name>
      <address>
        <city>Chungnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic university of Korea Daegu hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DongGuk university Gyeongju hospital</name>
      <address>
        <city>Gyeongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DongGuk university Ilsan hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje university Ilsan Paik hospital</name>
      <address>
        <city>Ilsan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon university Gil medical center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inha university hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeju national university hospital</name>
      <address>
        <city>Jeju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JeonNam university hospital</name>
      <address>
        <city>JeonNam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungbook National university hospital</name>
      <address>
        <city>Kyungbook</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeil hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea university Anam hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea university Guro hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyunghee university hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Seoul hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul national university hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic university St. Mary hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aju university hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>YoungNam university hospital</name>
      <address>
        <city>YoungNam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2014</study_first_submitted>
  <study_first_submitted_qc>June 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2014</study_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

